IDEXX Laboratories, Inc. (IDXX) EV/EBITDA Ratio: 30.48x
Is IDEXX Laboratories, Inc.’s EV/EBITDA ratio high or low?
IDEXX Laboratories, Inc.'s EV/EBITDA ratio of 30.48x is 20% below its 5-year average of 38.26x, near the low end of its 5-year range (23.90x–68.80x).
The EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX) is 30.48x as of Wednesday, June 10, 2026. It is below its 12-month average by 14.74% (35.75x).
IDXX EV/EBITDA Ratio Chart
IDXX Average EV/EBITDA Ratio Chart
IDXX Current vs Average EV/EBITDA Ratio Chart
IDXX EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
30.48x
EV/EBITDA RATIO AVG TTM
35.75x
EV/EBITDA RATIO AVG 3Y
34.46x
EV/EBITDA RATIO AVG 5Y
38.26x
EV/EBITDA RATIO AVG 10Y
38.52x
EV/EBITDA RATIO AVG 15Y
32.14x
EV/EBITDA RATIO AVG 20Y
28.65x
CURRENT VS TTM AVG
-14.74%
CURRENT VS 3Y AVG
-11.55%
CURRENT VS 5Y AVG
-20.33%
CURRENT VS 10Y AVG
-20.88%
CURRENT VS 15Y AVG
-5.15%
CURRENT VS 20Y AVG
+6.39%
IDXX Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 30.48x | 35.75x | 34.46x | 38.26x |
| Humana Inc. (HUM) | $43.78B | 18.61x | 11.68x | 11.33x | 12.36x |
| Agilent Technologies, Inc. (A) | $37.17B | 20.92x | 21.12x | 21.69x | 23.11x |
| Zoetis Inc. (ZTS) | $34.20B | 10.33x | 15.67x | 20.68x | 23.76x |
| Centene Corporation (CNC) | $31.94B | N/A | 4.99x | 7.28x | 9.49x |
| Medline Inc. (MDLN) | $30.90B | 13.75x | 15.00x | 15.00x | 15.00x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.90x | 13.19x | 14.98x | 17.09x |
| DexCom, Inc. (DXCM) | $29.24B | 23.24x | 28.10x | 43.48x | 70.03x |
| Biogen Inc. (BIIB) | $29.00B | 11.60x | 8.56x | 11.16x | 12.22x |
| Veeva Systems Inc. (VEEV) | $26.73B | 25.37x | 43.29x | 56.90x | 62.37x |
EV/EBITDA vs. its own history
At 30.5, EV/EBITDA is in its normal range — richer than 57% of its 20-year range.
20-year low
6.1
median
27.4
20-year high
68.8
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
IDEXX Laboratories, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The EV/EBITDA ratio for IDXX stock is 30.48x.
- Is IDEXX Laboratories, Inc.'s EV/EBITDA ratio high or low?
- IDEXX Laboratories, Inc.'s EV/EBITDA ratio of 30.48x is 20% below its 5-year average of 38.26x, near the low end of its 5-year range (23.90x–68.80x).
- What is the TTM average EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average EV/EBITDA ratio for IDXX stock is 35.75x.
- What is the 3Y average EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average EV/EBITDA ratio for IDXX stock is 34.46x.
- What is the 5Y average EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average EV/EBITDA ratio for IDXX stock is 38.26x.
- What is the 10Y average EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average EV/EBITDA ratio for IDXX stock is 38.52x.
- What is the 15Y average EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average EV/EBITDA ratio for IDXX stock is 32.14x.
- What is the 20Y average EV/EBITDA ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average EV/EBITDA ratio for IDXX stock is 28.65x.
IDEXX Laboratories, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-10 | 30.48x |
| 2026-06-09 | 31.30x |
| 2026-06-08 | 30.36x |
| 2026-06-05 | 30.41x |
| 2026-06-04 | 30.55x |
| 2026-06-03 | 30.33x |
| 2026-06-02 | 29.81x |
| 2026-06-01 | 30.65x |
| 2026-05-29 | 30.48x |
| 2026-05-28 | 30.72x |
| 2026-05-27 | 29.82x |
| 2026-05-26 | 30.15x |
| 2026-05-22 | 30.26x |
| 2026-05-21 | 29.93x |
| 2026-05-20 | 29.95x |
| 2026-05-19 | 29.58x |
| 2026-05-18 | 29.54x |
| 2026-05-15 | 28.64x |
| 2026-05-14 | 28.85x |
| 2026-05-13 | 28.63x |
| 2026-05-12 | 28.91x |
| 2026-05-11 | 28.81x |
| 2026-05-08 | 30.30x |
| 2026-05-07 | 30.94x |
| 2026-05-06 | 31.31x |
| 2026-05-05 | 30.45x |
| 2026-05-04 | 30.69x |
| 2026-05-01 | 30.92x |
| 2026-04-30 | 30.57x |
| 2026-04-29 | 30.18x |
| 2026-04-28 | 30.97x |
| 2026-04-27 | 31.32x |
| 2026-04-24 | 30.84x |
| 2026-04-23 | 30.57x |
| 2026-04-22 | 31.50x |
| 2026-04-21 | 31.00x |
| 2026-04-20 | 31.76x |
| 2026-04-17 | 32.09x |
| 2026-04-16 | 31.05x |
| 2026-04-15 | 31.63x |
| 2026-04-14 | 31.81x |
| 2026-04-13 | 31.27x |
| 2026-04-10 | 30.68x |
| 2026-04-09 | 31.85x |
| 2026-04-08 | 32.22x |
| 2026-04-07 | 31.31x |
| 2026-04-06 | 31.45x |
| 2026-04-02 | 31.03x |
| 2026-04-01 | 30.77x |
| 2026-03-31 | 30.62x |
| 2026-03-30 | 30.37x |
| 2026-03-27 | 30.43x |
| 2026-03-26 | 31.23x |
| 2026-03-25 | 31.36x |
| 2026-03-24 | 31.07x |
| 2026-03-23 | 31.51x |
| 2026-03-20 | 31.45x |
| 2026-03-19 | 31.58x |
| 2026-03-18 | 31.44x |
| 2026-03-17 | 31.96x |
| 2026-03-16 | 31.93x |
| 2026-03-13 | 31.26x |
| 2026-03-12 | 31.12x |
| 2026-03-11 | 32.69x |
| 2026-03-10 | 32.60x |
| 2026-03-09 | 33.22x |
| 2026-03-06 | 33.11x |
| 2026-03-05 | 33.67x |
| 2026-03-04 | 35.26x |
| 2026-03-03 | 34.56x |
| 2026-03-02 | 34.62x |
| 2026-02-27 | 35.69x |
| 2026-02-26 | 35.91x |
| 2026-02-25 | 35.73x |
| 2026-02-24 | 35.29x |
| 2026-02-23 | 33.90x |
| 2026-02-20 | 34.57x |
| 2026-02-19 | 35.67x |
| 2026-02-18 | 35.90x |
| 2026-02-17 | 35.42x |
| 2026-02-13 | 35.59x |
| 2026-02-12 | 34.92x |
| 2026-02-11 | 36.67x |
| 2026-02-10 | 36.55x |
| 2026-02-09 | 36.17x |
| 2026-02-06 | 36.44x |
| 2026-02-05 | 36.38x |
| 2026-02-04 | 36.35x |
| 2026-02-03 | 35.77x |
| 2026-02-02 | 36.16x |
| 2026-01-30 | 37.88x |
| 2026-01-29 | 38.23x |
| 2026-01-28 | 38.84x |
| 2026-01-27 | 39.23x |
| 2026-01-26 | 39.40x |
| 2026-01-23 | 39.18x |
| 2026-01-22 | 39.02x |
| 2026-01-21 | 39.32x |
| 2026-01-20 | 38.74x |
| 2026-01-16 | 40.37x |
| 2026-01-15 | 40.19x |
| 2026-01-14 | 40.10x |
| 2026-01-13 | 40.30x |
| 2026-01-12 | 40.90x |
| 2026-01-09 | 40.26x |
| 2026-01-08 | 40.21x |
| 2026-01-07 | 40.33x |
| 2026-01-06 | 39.90x |
| 2026-01-05 | 38.53x |
| 2026-01-02 | 37.85x |
| 2025-12-31 | 38.22x |
| 2025-12-30 | 38.54x |
| 2025-12-29 | 38.85x |
| 2025-12-26 | 38.88x |
| 2025-12-24 | 38.86x |
| 2025-12-23 | 38.54x |
| 2025-12-22 | 39.64x |
| 2025-12-19 | 39.54x |
| 2025-12-18 | 39.36x |
| 2025-12-17 | 39.27x |
| 2025-12-16 | 39.14x |
| 2025-12-15 | 39.55x |
| 2025-12-12 | 39.75x |
| 2025-12-11 | 39.94x |
| 2025-12-10 | 39.62x |
| 2025-12-09 | 39.47x |
| 2025-12-08 | 39.89x |
| 2025-12-05 | 40.30x |
| 2025-12-04 | 40.49x |
| 2025-12-03 | 40.96x |
| 2025-12-02 | 41.34x |
| 2025-12-01 | 41.13x |
| 2025-11-28 | 42.46x |
| 2025-11-26 | 42.63x |
| 2025-11-25 | 43.22x |
| 2025-11-24 | 42.42x |
| 2025-11-21 | 40.96x |
| 2025-11-20 | 38.93x |
| 2025-11-19 | 39.36x |
| 2025-11-18 | 37.86x |
| 2025-11-17 | 37.80x |
| 2025-11-14 | 38.96x |
| 2025-11-13 | 39.60x |
| 2025-11-12 | 40.27x |
| 2025-11-11 | 40.21x |
| 2025-11-10 | 40.05x |
| 2025-11-07 | 39.99x |
| 2025-11-06 | 40.28x |
| 2025-11-05 | 40.64x |
| 2025-11-04 | 40.75x |
| 2025-11-03 | 40.79x |
| 2025-10-31 | 37.14x |
| 2025-10-30 | 37.08x |
| 2025-10-29 | 37.03x |
| 2025-10-28 | 37.42x |
| 2025-10-27 | 38.17x |
| 2025-10-24 | 37.79x |
| 2025-10-23 | 37.66x |
| 2025-10-22 | 37.38x |
| 2025-10-21 | 37.58x |
| 2025-10-20 | 37.94x |
| 2025-10-17 | 37.48x |
| 2025-10-16 | 37.59x |
| 2025-10-15 | 37.69x |
| 2025-10-14 | 37.56x |
| 2025-10-13 | 37.36x |
| 2025-10-10 | 36.36x |
| 2025-10-09 | 37.09x |
| 2025-10-08 | 37.16x |
| 2025-10-07 | 37.01x |
| 2025-10-06 | 37.04x |
| 2025-10-03 | 37.23x |
| 2025-10-02 | 37.39x |
| 2025-10-01 | 36.59x |
| 2025-09-30 | 37.68x |
| 2025-09-29 | 37.20x |
| 2025-09-26 | 37.29x |
| 2025-09-25 | 36.48x |
| 2025-09-24 | 37.00x |
| 2025-09-23 | 38.23x |
| 2025-09-22 | 37.98x |
| 2025-09-19 | 38.68x |
| 2025-09-18 | 38.64x |
| 2025-09-17 | 37.79x |
| 2025-09-16 | 38.07x |
| 2025-09-15 | 37.97x |
| 2025-09-12 | 37.81x |
| 2025-09-11 | 38.04x |
| 2025-09-10 | 37.62x |
| 2025-09-09 | 38.64x |
| 2025-09-08 | 38.48x |
| 2025-09-05 | 37.92x |
| 2025-09-04 | 37.77x |
| 2025-09-03 | 37.39x |
| 2025-09-02 | 37.71x |
| 2025-08-29 | 38.15x |
| 2025-08-28 | 38.15x |
| 2025-08-27 | 37.79x |
| 2025-08-26 | 37.84x |
| 2025-08-25 | 37.82x |
| 2025-08-22 | 38.06x |
| 2025-08-21 | 37.34x |
| 2025-08-20 | 37.73x |
| 2025-08-19 | 37.55x |
| 2025-08-18 | 37.62x |
| 2025-08-15 | 38.37x |
| 2025-08-14 | 38.55x |
| 2025-08-13 | 39.13x |
| 2025-08-12 | 38.45x |
| 2025-08-11 | 38.44x |
| 2025-08-08 | 38.79x |
| 2025-08-07 | 38.32x |
| 2025-08-06 | 36.83x |
| 2025-08-05 | 37.86x |
| 2025-08-04 | 40.21x |
| 2025-08-01 | 34.62x |
| 2025-07-31 | 34.54x |
| 2025-07-30 | 36.94x |
| 2025-07-29 | 37.00x |
| 2025-07-28 | 36.58x |
| 2025-07-25 | 36.50x |
| 2025-07-24 | 35.53x |
| 2025-07-23 | 34.95x |
| 2025-07-22 | 34.40x |
| 2025-07-21 | 33.69x |
| 2025-07-18 | 33.29x |
| 2025-07-17 | 33.55x |
| 2025-07-16 | 33.67x |
| 2025-07-15 | 34.06x |
| 2025-07-14 | 34.36x |
| 2025-07-11 | 34.48x |
| 2025-07-10 | 34.97x |
| 2025-07-09 | 34.94x |
| 2025-07-08 | 34.83x |
| 2025-07-07 | 35.26x |
| 2025-07-03 | 35.35x |
| 2025-07-02 | 35.07x |
| 2025-07-01 | 35.07x |
| 2025-06-30 | 34.67x |
| 2025-06-27 | 34.35x |
| 2025-06-26 | 34.13x |
| 2025-06-25 | 34.29x |
| 2025-06-24 | 34.30x |
| 2025-06-23 | 33.93x |
| 2025-06-20 | 33.88x |
| 2025-06-18 | 33.63x |
| 2025-06-17 | 33.67x |
| 2025-06-16 | 34.19x |
| 2025-06-13 | 33.81x |
| 2025-06-12 | 34.07x |
| 2025-06-11 | 33.90x |
| 2025-06-10 | 34.01x |
| 2025-06-09 | 33.55x |
| 2025-06-06 | 33.95x |
| 2025-06-05 | 33.78x |
| 2025-06-04 | 33.94x |
| 2025-06-03 | 34.01x |
| 2025-06-02 | 33.31x |
| 2025-05-30 | 33.22x |
| 2025-05-29 | 33.35x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky